Ilaris (canakinumab) costs roughly $96,000 or more per patient per year, making it one of the most expensive drugs on the market. Several factors drive that price: it treats extremely rare diseases, it’s a biologic that requires complex manufacturing, Novartis holds exclusive market rights with no biosimilar competition in sight, and a massive clinical trial for a broader use ultimately failed to pay off.
Orphan Drug Status and Tiny Patient Populations
Ilaris is approved to treat a collection of rare autoinflammatory conditions, including familial Mediterranean fever, Muckle-Wells syndrome, tumor necrosis factor receptor-associated periodic syndrome, and systemic-onset juvenile idiopathic arthritis. In 2020, it also received approval for adult-onset Still disease. Each of these conditions affects a very small number of people.
Because these diseases are so rare, Ilaris carries orphan drug designation from the FDA. This designation grants Novartis seven years of market exclusivity per approved indication and provides tax credits for clinical trial costs. The trade-off is straightforward: orphan drug incentives exist because pharmaceutical companies would otherwise have little financial reason to develop treatments for diseases that affect only a few thousand patients. But they also mean the full cost of development, manufacturing, and profit must be spread across that small group. When your customer base is measured in thousands rather than millions, the per-patient price climbs dramatically.
Biologic Manufacturing Is Inherently Costly
Ilaris is not a simple pill made from chemical ingredients. It’s a monoclonal antibody, a type of biologic drug produced by living mammalian cells grown in large-scale fermentation systems. Every marketed monoclonal antibody is made this way, and the process is expensive at every stage. The cells must be carefully maintained, the production yields depend on precise fermentation conditions, and the final product requires extensive purification and quality testing.
Monoclonal antibodies also tend to be needed in relatively high doses, often measured in grams rather than the milligrams typical of conventional drugs. That means manufacturers need large-scale production capacity to meet demand, even when the patient population is small. The combination of complex living-cell manufacturing and high per-dose quantities makes biologics fundamentally more expensive to produce than traditional small-molecule medications.
A Billion-Dollar Bet on Heart Disease That Didn’t Pay Off
Novartis invested heavily in trying to expand Ilaris beyond rare diseases. The CANTOS trial, a landmark cardiovascular study, enrolled over 10,000 patients to test whether canakinumab could reduce heart attacks and strokes by targeting inflammation. The trial did show a modest benefit, but the FDA ultimately declined to approve canakinumab for atherosclerotic cardiovascular disease, issuing a complete response letter to Novartis.
That rejection was a significant financial blow. A cardiovascular approval would have opened Ilaris to millions of potential patients, spreading development costs across a vastly larger market and potentially allowing a lower per-patient price. Instead, the enormous expense of running a 10,000-person global trial sits on the balance sheet with no new revenue stream to offset it. The cost of that failed expansion is, in effect, folded into the pricing of Ilaris for its existing rare disease indications. The independent drug evaluation body ICER had planned a cost-effectiveness review of canakinumab for heart disease but canceled it after the FDA’s rejection.
No Biosimilar Competition on the Horizon
For most expensive biologics, the eventual arrival of biosimilars (the biologic equivalent of generic drugs) brings prices down. That relief is nowhere close for Ilaris. As of mid-2025, the only known biosimilar development effort for canakinumab is from Alvotech, and it’s still in early research stages, not yet in clinical trials. Given that biosimilar development for monoclonal antibodies typically takes years of clinical testing and regulatory review, patients and insurers are unlikely to see a lower-cost alternative anytime soon.
The competitive landscape among existing drugs is also limited. Other medications that target the same inflammatory pathway exist, but Ilaris has a dosing advantage that reinforces its market position: it’s given as a single injection under the skin once every eight weeks. Competing treatments require far more frequent dosing, which can mean daily or weekly injections. That convenience factor helps Ilaris maintain its premium pricing.
What Patients Actually Pay
The list price of Ilaris is not necessarily what patients pay out of pocket, though the gap between list price and actual cost depends heavily on insurance coverage. Novartis runs the Novartis Patient Assistance Foundation, which provides Ilaris at no cost to qualifying patients. Eligibility is based on household income and out-of-pocket burden. For a single person in the continental United States, household income must be below $87,480 (as of 2023 guidelines). For a family of four, the threshold is $180,000. Limits are higher in Alaska and Hawaii.
There’s an additional requirement for most insured patients: your out-of-pocket cost for the medication must represent at least 8% of your annual household income. Uninsured patients and those on Medicare face different criteria. If you’re prescribed Ilaris and the cost is a barrier, Novartis’s patient assistance program is the first place to check. Specialty pharmacies and disease-specific foundations sometimes offer additional support as well.
Why the Price Is Unlikely to Drop Soon
Ilaris sits at the intersection of every factor that drives drug prices up: orphan drug exclusivity, biologic manufacturing complexity, a tiny patient population, no generic or biosimilar competition, and sunk costs from a failed expansion into a larger market. Each of these factors alone would push prices higher. Together, they create a situation where a six-figure annual cost is the predictable outcome of how rare disease drugs are developed, manufactured, and sold in the current system. Until a biosimilar reaches the market or the patent landscape shifts, the pricing structure for Ilaris is unlikely to change in any meaningful way.